The California-based company was founded in 2008 and specializes in utilizing site-specific modification technology to create homogenous hybrid biotherapeutics. Redwood Bioscience's drug conjugate optimization combines the benefits of biologic carriers with the potency advantages of small molecule and synthetic peptide cargo, overcoming significant challenges associated with conjugating biologics to synthetic molecules. Their products offer improved binding specificity and half-life benefits, making them a promising player in the biotherapeutics market.